Atara Biotherapeutics (ATRA) Earns Outperform Rating from William Blair

William Blair reiterated their outperform rating on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report issued on Monday, AnalystRatings.com reports. William Blair also issued estimates for Atara Biotherapeutics’ Q1 2020 earnings at ($1.41) EPS, Q2 2020 earnings at ($1.41) EPS, Q3 2020 earnings at ($1.40) EPS and Q4 2020 earnings at ($1.35) EPS.

“We view the results as very promising given the high efficacy and very favorable safety profile, with no evidence of on-target, off-tumor toxicity of the CAR-T therapy . Given the strong expression of mesothelin across several tumor types, including mesothelioma (90%-plus), lung adenocarcinoma (60%-plus), triple negative breast cancer (TNBC, 35%), and pancreatic cancer (80%), the opportunity for a mesothelin- CAR-T therapy with a strong safety profile is significant.”,” the firm’s analyst commented.

A number of other equities analysts have also commented on ATRA. Zacks Investment Research lowered Atara Biotherapeutics from a hold rating to a sell rating in a research note on Monday, December 24th. Mizuho restated a buy rating and set a $62.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. Cowen restated a buy rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. BidaskClub upgraded Atara Biotherapeutics from a hold rating to a buy rating in a research report on Thursday, February 7th. Finally, ValuEngine downgraded Atara Biotherapeutics from a strong-buy rating to a buy rating in a research report on Tuesday, February 12th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and an average price target of $50.17.

Shares of Atara Biotherapeutics stock opened at $40.72 on Monday. Atara Biotherapeutics has a 12 month low of $27.85 and a 12 month high of $54.45. The company has a market cap of $1.85 billion, a P/E ratio of -7.73 and a beta of 2.25.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.44). On average, equities analysts anticipate that Atara Biotherapeutics will post -5.99 EPS for the current year.

In other Atara Biotherapeutics news, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $39.96, for a total transaction of $59,940.00. Following the sale, the insider now directly owns 63,646 shares in the company, valued at $2,543,294.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Christopher Haqq sold 775 shares of the company’s stock in a transaction that occurred on Friday, February 15th. The shares were sold at an average price of $39.59, for a total value of $30,682.25. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 166,424 shares of company stock worth $6,195,005. Company insiders own 10.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of ATRA. Deutsche Bank AG raised its holdings in shares of Atara Biotherapeutics by 79.7% in the fourth quarter. Deutsche Bank AG now owns 221,084 shares of the biotechnology company’s stock worth $7,678,000 after buying an additional 98,042 shares during the period. Geode Capital Management LLC raised its holdings in shares of Atara Biotherapeutics by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 498,078 shares of the biotechnology company’s stock worth $17,303,000 after buying an additional 46,546 shares during the period. Norges Bank purchased a new stake in shares of Atara Biotherapeutics in the fourth quarter worth approximately $20,648,000. Dimensional Fund Advisors LP raised its holdings in shares of Atara Biotherapeutics by 107.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 474,973 shares of the biotechnology company’s stock worth $16,500,000 after buying an additional 245,832 shares during the period. Finally, FMR LLC raised its holdings in shares of Atara Biotherapeutics by 1.8% in the fourth quarter. FMR LLC now owns 5,274,169 shares of the biotechnology company’s stock worth $183,225,000 after buying an additional 93,432 shares during the period.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Featured Story: Trading Strategy Methods for Individual Investors

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit